Table 1.
Full-text case reports and letters to editor about clinical response after COVID-19 infection in the literature
| Author | Age | Sex | Diagnosis | Date of diagnosis | Prior treatment and clinical course | Date of COVID-19 infection | Response after COVID-19 infection |
|---|---|---|---|---|---|---|---|
| Herrscher et al. 2019 [6] | 84 | F | Melanoma harboring BRAFV600E mutation | February 2020 | Dabrafenib-trametinib and 20 Gy irradiation to metastatic cervical lymph node | January 2021 | Objective tumor response and reduction in size of all metastases |
| Pasin et al [7] | 20 | M | Relapsed/Refractory NK/T-cell lymphoma associated with EBV and AIHA | July 2018 (the initial record which available) | Rituximab, pembrolizumab, L-asparaginase, intravenous immunoglobulin, etoposide, SMILE, DDGP and CHOP chemotherapy | April 2020 | EBV-DNA levels decreased, and spleen enlargement was reduced, a remission of the NK lymphoma was observed |
| Challenor and Tucker [8] | 61 | M | EBV positive Hodgkin lymphoma | N/A | No prior therapy. | Immediately after diagnosis | EBV-DNA values decreased, and disease activity regressed significantly in PET/CT scan |
| Sollini et al 2021 [9] | 61 | M | Follicular lymphoma | September 2019 | Rituximab and bendamustine | April 2020 | Partial response after treatment with rituximab-bendamustine and complete response after COVID-19 |
| Rudolphi-Solero et al [10] | 55 | M | Follicular lymphoma | 2014, relaps in June 2020 | Remission after R-CHOP in 2016. Two cycles of ESHAP after relapse in June 2020 (last in September 2020) | December 16, 2020 (the date of post-COVID-19 imaging) | Interpreted as a partial response without any treatment. |
| Antwi-Amoabeng et al [11] | 76 | F | Multiple myeloma | June 2020 | One cycle of CyBorD | August 2020 | Normocellular bone marrow seen without increase in blast or plasma cells |
| Current patient | 81 | F | High grade B cell Lymphoma | April 2021 | One cycle of R-CHOP | May 2021 | Complete metabolic response on FDG PET/CT |
Abbreviations: AIHA = autoimmune hemolytic anemia; EBV = Epstein-Barr virus; F = female; M = male; CyBorD = cyclophosphamide, bortezomib and dexamethasone; DDGP = cisplatin, dexamethasone, gemcitabine and pegaspargase; ESHAP = etoposide, methylprednisolone (solumedrol), high-dose cytarabine (Ara-C), and cisplatin; R-CHOP = rituximab, cyclophosphamide, hydroxydaunorubicin (doxorubicin), vincristine (Oncovin) and prednisone; SMILE = dexamethasone, methotrexate, ifosfamide, l-asparaginase and etoposide.